butamidine has been researched along with cycloguanil in 1 studies
| Studies (butamidine) | Trials (butamidine) | Recent Studies (post-2010) (butamidine) | Studies (cycloguanil) | Trials (cycloguanil) | Recent Studies (post-2010) (cycloguanil) |
|---|---|---|---|---|---|
| 9 | 0 | 2 | 231 | 16 | 37 |
| Protein | Taxonomy | butamidine (IC50) | cycloguanil (IC50) |
|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 5.8 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 2.985 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.45 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queener, SF | 1 |
1 review(s) available for butamidine and cycloguanil
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |